Neuropeptide Receptors: Novel Targets for HIV/AIDS Therapeutics
Neuropeptide Receptors: Novel Targets for HIV/AIDS Therapeutics
复制标题
DOI：
10.3390/ph4030485
复制
发表时间：
2011-03-09
期刊：
影响因子：
4.6
通讯作者：
Branch DR
中科院分区：
文献类型：
--
作者：
Branch DR
血管活性肠肽/垂体腺苷酸环化酶激活多肽（VPAC）受体在许多生理功能中具有重要作用，包括葡萄糖稳态、神经保护、记忆、肠道功能、免疫系统调节和昼夜节律功能。此外，VPAC受体已被证明在体外通过信号转导途径调节HIV感染，该信号转导途径似乎调节病毒整合。本文将对VPAC刺激对HIV感染的影响进行综述，并介绍针对这些受体的HIV/AIDS治疗方法的开发方法。迫切需要新的艾滋病毒/艾滋病治疗方法，以阻止这种疾病的继续蔓延，特别是在不发达国家。抑制VPAC1信号传导和刺激VPAC2信号传导的药物设计可能会导致治疗和/或预防艾滋病毒/艾滋病的替代疗法。
The vasoactive intestinal peptide/pituitary adenylyl cyclase-activating polypepetide (VPAC) receptors are important for many physiologic functions, including glucose homeostasis, neuroprotection, memory, gut function, modulation of the immune system and circadian function. In addition, VPAC receptors have been shown to function in vitro to modulate the infection of HIV by a signal transduction pathway that appears to regulate viral integration. In this article, the affects of VPAC stimulation on HIV infection will be reviewed and approaches for the development of HIV/AIDS therapeutics that target these receptors will be described. Novel HIV/AIDS therapeutics are urgently required to stem the continued spread of this disease, particularly in underdeveloped countries. Drug design to inhibit signaling through VPAC1 and stimulate signaling through VPAC2 could lead to alternative therapies for the treatment and/or prevention of HIV/AIDS.